請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72428
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李章銘 | |
dc.contributor.author | Jian-Xun Chen | en |
dc.contributor.author | 陳建勳 | zh_TW |
dc.date.accessioned | 2021-06-17T06:41:59Z | - |
dc.date.available | 2023-09-04 | |
dc.date.copyright | 2018-09-04 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-15 | |
dc.identifier.citation | Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007;13:1585 -94.
Akhtar S. Areca nut chewing and esophageal squamous -cell carcinoma risk in Asians: a meta -analysis of case -control studies. Cancer Causes Control 2013;24:257 -65. Akutsu Y, Shuto K, Kono T, et al. The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. J Surg Oncol 2012;105:756 -60. Al -Taan OS, Eltweri A , Sharpe D, Rodgers PM, Ubhi SS, Bowrey DJ. Prognostic value of baseline FDG uptake on PET -CT in esophageal carcinoma. World J Gastrointest Oncol 2014;6:139 -44. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histol ogical subtype in 2012. Gut 2015;64:381 -7. Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F -FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med 2012;53:864 -71. Bar -Shalom R, Guralnik L, Tsalic M, et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer . Eur J Nucl Med Mol Imaging 2005;32:918-24 Bhutani MS, Hawes RH, Hoffman BJ. A comparison of the accuracy echo features during endoscopic ultrasound (EUS) and EUS -guided fine -needle aspiration for diagnosis of malignant lymph node invasion. Gastrointest Endosc 1997;45:474 -9. Blodgett TM, Meltzer CC, Townsen d DW. PET/CT: form and function . Radiology 2007;242:360 -85. Blom RL, Schreurs WM, Belgers HJ, Oosten brug LE, Vliegen RF, Sosef MN. The value of post -neoadjuvant therapy PET -CT in the detection of interval metastases in esophageal carcinoma . Eur J Surg Onco l 2011;37:774 -8. Bollschweiler E, Holscher AH, Metzger R, et al. Prognostic significance of a new grading system lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg 2011;92:2020 -7. Brown C, Howes B, Jamieson GG, et al. Accuracy of PET -CT in predicting survival in patients with esophageal cancer. World J Surg 2012;36:1089 -95. Catalano MF, Sivak MV, Jr., Rice T, Gragg LA, Van Dam J. Endosonographic features predictive of lymph node metastasis. Gastrointest Endos c 1994;40:442 -6. Chen MF, Yang YH, Lai CH, PC, WC. Outcome of patients with esophageal cancer: a nationwide analysis. Ann Surg Oncol 2013;20:3023-30 Chisholm EM, Williams SR, Leung JW, Chung SC, Van Hasselt CA, Li AK. Lugol's iodine dye -enhanced endoscopy in patients with cancer of the oesophagus and head neck. Eur J Surg Oncol 1992;18:550 -2. D'Journo XB, Thomas PA. Current management of esophageal cancer. J Thorac Dis 2014;6 Suppl 2:S253 -64. De Stefani E, Barrios Fierro L. Bla ck (air -cured) and blond (flue -cured) tobacco and cancer risk. III: Oesophageal cancer. Eur J Cancer 1993;29A:763 -6. Dietrich CF, Jenssen C, Arcidiacono PG, et al. Endoscopic ultrasound: Elastographic lymph node evaluation. Endosc Ultrasound 2015;4:176 -90. Dumonceau JM, Polkowski M, Larghi A, et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS) -guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2011;43:897 -912. Edgren G, Adami HO, Weiderpass E, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013;62:1406 -14. Eloubeidi MA, Cerfolio RJ, Bryant AS, Varadarajulu S. Efficacy of endoscopic ultrasound in patients with esophageal cancer predi cted to have N0 disease . Eur J Cardiothorac Surg 2011;40:636 -41. Eloubeidi MA, Wallace MB, Reed CE, et al. The utility of EUS and -guided fine needle aspiration in detecting celiac lymph node metastasis in patients with esophageal cancer: a single -cente r experience. Gastrointest Endosc 2001;54:714-9 Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241 -52. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893 -917. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359 -86. Flamen P, Lerut A, Van Cutsem E, et al. Utility of posi tron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202 -10. Gillies RS, Middleton MR, Maynard ND, Bradley KM, Gleeson FV. Additional benefit of (1)(8)F -fluorodeoxyglucose integrated pos itron emission tomography/computed tomography in the staging of oesophageal cancer. Eur Radiol 2011;21:274 -80. Global Burden of Disease Cancer C, Fitzmaurice Allen et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability -Adjusted Life -years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3:524 -48. Guo H, Zhu Xi Y, et al. Diagnostic and prognostic value of 18F -FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus . J Nucl Med 2007;48:1251 -8 mai Y, Hihara J, Emi M, et al. Ability of Fluorine -18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma . Ann Thorac Surg 2016;102:1132 -9. Hamai Y, Hihara J, Emi M, et al. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treat ed with Neoadjuvant Chemoradiotherapy Followed by Surgery. World J Surg 2018;42:1496 -505. Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol 2012;41:1706 -18. Jeon JH, Lee JM, Moon DH, et al. Prognostic significance of venous invasion and maximum standardized uptake value of 18F -FDG PET/CT in surgically resected T1N0 esophageal squamous cell carcinoma. Eur J Surg Oncol 2017;43:471 -7. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24: 2137 -50. Kato H, Kuwano Nakajima M, et al. Comparison between positron emission tomography and computed in the use of assessment of esophageal carcinoma . Cancer 2002;94:921 -8 Kato H, Miyazaki T, Nakajima M, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005;103:148 -56. Kawano T, Ohshima M, Iwai T. Early esophageal carcinoma: endoscopic ultrasonography using the Sonoprobe. Abdom Imaging 200 3;28:477 -85. Konski A, Doss M, Milestone B, et al. The integration of 18 -fluoro -deoxy -glucose positron emission tomography and endoscopic ultrasound in the treatment -planning process for esophageal carcinoma . Int J Radiat Oncol Biol Phys 2005;61:1123 -8. Ku kar M, Alnaji RM, Jabi F, et al. Role of Repeat 18F -Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma. JAMA Surg 2015;150:555 -62. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825 -31. Lee CH, Wu DC, JM, et al. Carcinogenetic impact of alcohol intake on squamous cell carcinoma risk of th e oesophagus in relation to tobacco smoking. Eur J Cancer 2007;43:1188 -99. Lee WC, TH, Jang JY, et al. Staging accuracy of endoscopic ultrasound performed by nonexpert endosonographers in patients with resectable esophageal squamous cell carcinoma: is it possible? Dis Esophagus 2015;28:574 -8 Leng XF, Zhu Y, Wang GP, Jin J, Xian L, Zhang YH. Accuracy of ultrasound for the diagnosis of cervical lymph node metastasis in esophageal cancer: a systematic review and meta -analysis. J Thorac Dis 2016;8:2146 -57. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG -PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy . An n Surg 2000;232:743 -52. Lu CL, Lang HC, Luo JC, et al. Increasing trend of the incidence esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control 2010;21:269 -74. Luketich JD, Schauer PR, Meltzer CC, et al. Role of pos itron emission tomography in staging esophageal cancer . Ann Thorac Surg 1997;64:765 -9. Manabe O, Hattori N, Hirata K, et al. Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal ca ncer . J Nucl Med 2013;54:670 -6. May A, Gunter E, Roth F, et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004;53:634 -40. Meltzer C C, Luketich JD, Friedman D, et al. Whole -body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 2000;25:882 -7 Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma the oesophagus gastric cardia: a prospective cohort study. Gut 2007;56:1503 -11. Miyata H, Y amasaki M, Takahashi T, et al. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F -fluorodeoxiglucose positron emission tomography (18F -FDG -PET) . Ann Surg Oncol 2014;21:575 -82. Monjazeb AM, Riedlinger G, Aklilu M, et al. Outcomes of patients with esophageal cancer staged with [(1)(8)F]fluorodeoxyglucose positron emission tomography (FDG -PET): can postchemoradiotherapy FDG -PET predict the utility of resection? . J Clin Oncol 2010;28:4714 -21. Nieman DR, Peyre CG, Watson TJ, et al. Neoadjuvant treatment response in negative nodes is an important prognosticator after esophagectomy. Ann Thorac Surg 2015;99:277 -83. Omloo JM, van Heijl M, Hoekstra OS, Berge Henegouwen MI, Lanschot JJ, Sloof GW. FDG -PET parameters as prognostic factor in esophageal cancer patients: a review . Ann Surg Oncol 2011;18:3338 -52. Pech O, Gunter E, Dusemund F, Orig er J, Lorenz D, Ell C. Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer. Endoscopy 2010;42:456 -61. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma . Lancet 2013;381:400 -12. Piessen G, Petyt Duhamel A, M irabel X, Huglo D, Mariette C. Ineffectiveness of (1)(8)F -fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion neoadjuvant chemoradiation in esophageal cancer . Ann Surg 2013;258:66 -76. Port JL, Lee PC, Korst RJ, et al. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma . A nn Thorac Surg 2007;84:393 -400. Puli SR, Reddy JB, Bechtold ML, Antillon D, Ibdah JA, MR. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta -analysis and systematic review. World J Gastroenterol 2008;14:1479 -90. Rampado S, Bocus P, Battaglia G, Ruol A, Portale Ancona E. Endoscopic ultras ound: accuracy in staging superficial carcinomas of the esophagus. Ann Thorac Surg 2008;85:251 -6. Rebollo Aguirre AC, Ramos -Font C, Villegas Portero R, Cook GJ, Llamas Elvira JM, Tabares AR. 18F -fluorodeoxiglucose positron emission tomography for the evalu ation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature . Ann Surg 2009;250:247 -54. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010;17:1721 -4. Rustgi AK, El -Serag HB. Esophageal carcinoma. N Engl J Med 2014;371:24 99 -509. Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer -- an overview. Nat Rev Gastroenterol Hepatol 2013;10:230 -44. Shah PM, Gerdes H. Endoscopic options for early stage esophageal cancer. J Gastrointest Oncol 2015;6:20 -30. Shaheen NJ, Richter JE. Bar rett's oesophagus. Lancet 2009;373:850 -61. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009;361:2548 -56. Shapiro J, Biermann K, van Klaveren D, et al. Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Ne oadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer. Ann Surg 2017;265:356 -62. Smith BR, Chang KJ, Lee JG, Nguyen NT. Staging accuracy of endoscopic ultrasound based on pathologic analysis after minimally invasive esophagectomy . Am Surg 2010;76:1228 -31. Song SY, Kim JH, Ryu JS, et al. FDG -PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer . Int J Radiat Oncol Biol Phys 2005;63:1053 -9. Sun F, Chen T, Han J, Ye P, Hu J. Staging accuracy of endoscopic ultrasound for esophageal cancer after neoadjuvant chemotherapy: a meta -analysis and systematic review . Dis Esophagus 2015;28:757 -71. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer . Ann Thorac Surg 2004;78:1152 -60; discussion -60. van Heijl M, Omloo JM, Berge Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadju vant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 2011;253:56 -63. van Vliet EP, Heijenbrok -Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta -analysis. Br J Cancer 2008;98 :547 -57. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85 -92. Wani S, Das A, Rastogi A, et al. Endoscopic ultrasonography in esophageal cancer leads to improved survival rates: results from a population -based study. Cancer 2015;121:194 -201. Whiteman DC, Sadeghi S, Pandeya N, et al. Combined effects of obesity, acid reflux and smok ing on the risk of adenocarcinomas oesophagus. Gut 2008;57:173 -80. Wu IC, CC, Lu CY, et al. Substance use (alcohol, areca nut and cigarette) is associated with poor prognosis of esophageal squamous cell carcinoma. PLoS One 2013;8:e55834. Yasud a T, Higuchi I, Yano M, et al. The impact of (1)(8)F -fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma . Ann Surg Oncol 2012;19:652 -60. Yasuda T, Yano M, Miyata H, et al. Prognostic Significance of (18)F -fluorodeoxyglucose Positron Emission Tomography (FDG -PET) -Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma . A nn Surg Oncol 2015;22:2599 -607. Yuan S, Yu Y, Chao KS, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer . J Nucl Med 2006;47:1255 -9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72428 | - |
dc.description.abstract | 食道癌是目前全世界上主要的症死因之一,其五年存活率低於 15% 。鱗狀上皮細胞 癌及腺是兩種主要的食道細胞型態。在台灣,鱗狀上皮佔超過八成以病患。針對食道癌的症評估包括史、身體檢查攝影電腦斷層掃描、內視鏡超音波及正子造影檢查。食道癌的治療方式則包括化學放射線療、以及食道切除暨重建手術,而治策略的選擇則是根據開始前臨床期別來做決定。針對可切除的局部侵犯性食道癌,目前治療主要建議策略是輔助化學及放射線治療搭配食道切除手術來達成。針對這個族群的預後研究傳統上仍是 以手術 後的病理期別作為判斷依據。然而臨床上即便在治療相同患中,仍有一定的比例會疾病復發。因此在這篇研究中,我們主要探討群接受過前輔助性化學及放射線治療 搭配食道切除的手術患者中,在最初治療前正子造影檢查分期上是否 扮演 影響預後 的角色 。本研究中共收集 187 位患者,依據最初在治療前的正子造影檢 查不同分期作析,發現對於手術的病理別以及後續疾復率在統計學上有意義。此外,針對其中病理期別為 N0 的 125 位病患,同樣依據最初治療前的正子造影 檢查做分組,一樣可以發現到最初治療前的正子造影期對於後續 的疾病復發有統計 學上的意義。因此,依據研究結論我們建議將最初治療前正子造影分期納入可切除的局部侵犯性食道癌患者治療考量及追蹤計畫。 | zh_TW |
dc.description.abstract | Esophageal cancer is a major cause of death worldwide and the 5 -year overall survival was less than 15%. Squamous cell carcinoma (SCC) and adenocarcinoma are the two predominant histological subtypes. In Taiwan, SCC accounted for more than 80% of all esophageal cancer. Cancer staging evaluations included medical history, physical examination, esophagogr am, computer tomography (CT), endoscopic ultrasound EUS), and positron emission tomography (PET). Treatment strategies including chemotherapy, radiotherapy, and esophagectomy with reconstruction were based on the clinical evaluation. For resectable locally advanced esophageal cancer, neoadjuvant therapy following esophagectomy was suggested. Traditionally , prognostic factors for these population were mainly focused on pathologic results. However, a certain proportion of patients with the same pathologic st age would showed different outcome. In this study, we investigated the impact of pre -CCRT PET scan (pretreatment scan) on the prognosis of patients after CCRT and esophagectomy. In analysis 187 patients enrolled in this study, N status evaluated by pretreatment PET scan (pre-CCRT PET -N) was significantly associated with pathologic N status and tumor recurrence rate. Further focused on 125 patients with pathologic N0, pre-CCRT PET -N status also showed powerful stratification in the recurrence rate and disease -free survival. Therefore, we recommended pre-CCRT PET -N status should be taken into consideration in the treatment strategies for resectable locally advanced esophageal cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:41:59Z (GMT). No. of bitstreams: 1 ntu-107-P02421017-1.pdf: 1756626 bytes, checksum: 33e0c138b15990894e7674ce1d4bf01e (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書 ………………………………………………………………………. i
誌謝 ………………………………………………………………………………………. ii 中文摘要 …………………………………………………………………………………. iii 英文摘要 …………………………………………………………………………………. iv 碩士論文內容 第一章 緒論 …………………………………………………………………. 1 第二章 研究方法與材料 …………………………………………………..…. 11 第 三 章 結果 ………………………………………………………………….. 14 第 四 章 討論 ………………………………………………………………….. 18 第五 章 結論 ..…………………………………………………………….….. 23 第六 章 展望 ……………………………………………………………….….. 24 第 七 章 論文英文簡述 …………………………………………………….….. 25 第 八 章 參考文獻 ……………………………………………………………….. 28 表 1、表 2等……………………………………………………………………………… 40 圖 1、圖 2等……………………………………………………………………………… 52 | |
dc.language.iso | zh-TW | |
dc.title | 前輔助治療前正子造影的臨床分期對食道癌術後的影響 | zh_TW |
dc.title | The impact of pre-CCRT clinical stage by positron emission tomography (PET) on patients after esophagectomy | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊偉勛,方信元 | |
dc.subject.keyword | 食道癌,輔助性化學及放射線治療,食道癌切除手術,正子造影, | zh_TW |
dc.subject.keyword | esophageal cancer,CCRT,esophagectomy,PET, | en |
dc.relation.page | 62 | |
dc.identifier.doi | 10.6342/NTU201803413 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 1.72 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。